DHR Earnings Prediction
The chart below shows how DHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DHR sees a -0.37% change in stock price 10 days leading up to the earnings, and a -1.54% change 10 days following the report. On the earnings day itself, the stock moves by -1.29%. This data can give you a slight idea of what to expect for the next quarter's release.
DHR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
6.54B
142.78%
12.76%
Gross Margin
59.50%
-1.28%
1.43%
Operating Margin
23.31%
8.62%
14.55%
Net Margin
16.61%
-16.53%
17.72%
EPS
1.49
2.76%
33.04%
No Data Available
DHR Earnings Analysis
Danaher Corp Corporation (DHR.N) Earnings Conference Call
Positive
Q4 2024 Sales Performance: Sales for Q4 2024 reached $6.5 billion, reflecting a 1% core revenue growth, demonstrating resilience in the company's performance despite market challenges.
Improved Operating Profit Margin: Adjusted operating profit margin for Q4 improved by 90 basis points to 29.6%, driven by effective cost savings initiatives, highlighting operational efficiency.
Strong Free Cash Flow: Free cash flow generated in Q4 amounted to $1.5 billion, contributing to a robust free cash flow to net income conversion ratio of approximately 135% for the year, underscoring strong cash generation capabilities.
Bioprocessing Revenue Growth: The bioprocessing segment experienced high single-digit core revenue growth, with a sustained positive momentum in order growth for six consecutive quarters, indicating strong demand in this area.
Share Repurchase Strategy: Danaher deployed approximately $7 billion towards share repurchases in 2024, including 28 million shares, reflecting confidence in the company's value and commitment to returning capital to shareholders.
Negative
Core Revenue Decline: Core revenue declined 1.5% year over year, indicating a decrease in overall sales performance for the company.
Diagnostics Revenue Decline: Core revenue in the Diagnostics segment decreased by 2%, reflecting challenges in this area compared to previous periods.
Genomics Revenue Decline: Core revenue in the genomics consumables business declined in the quarter, with growth in next generation sequencing products not enough to offset losses in other areas.
Core Revenue Decline Forecast: The guidance for Q1 2025 anticipates a low single digit decline in core revenue, suggesting continued struggles in the upcoming quarter.
Operating Profit Margin Decline: The adjusted operating profit margin for 2025 is expected to decrease to approximately 26.5%, down from previous levels, indicating potential pressure on profitability.
DHR FAQs
How does DHR typically perform around its earnings report dates?
Is Danaher Corp (DHR) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DHR Earning Call Sentiment
Earnings call transcript: Danaher Q4 2024 sees revenue beat, stock rises
DHR.N
2.38%Positive
The earnings call presents a mixed picture: strong cash flow and operational performance, yet challenges like competitive pressures in diagnostics, supply chain issues, and a cautious revenue guidance. The share repurchase program is a positive, but offset by weak guidance and external challenges. The Q&A section reveals management's cautious stance and lack of clear guidance, which may not inspire confidence. Overall, the sentiment is neutral as positive aspects are countered by uncertainties and challenges.
